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Introduction: The objective of this study was to directly compare the safety of tocilizumab (TCZ) and TNF
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(PY)] or TNFIs [TNFI group, n = 304, 231.01 PY] from 2008 to 2011 in the registry of Japanese RA patients on biologics
for long-term safety registry. We assessed types and incidence rates (IRs) of serious adverse events (SAEs) and serious
infections (SIs) during the first year of treatment. Risks of the biologics for SAEs or SIs were calculated using the Cox
regression hazard analysis.
Results: Patients in the TCZ group had longer disease duration (P <0.001), higher disease activity (P = 0.019) and more
frequently used concomitant corticosteroids (P <0.001) than those in the TNFI group. The crude IR (/100 PY) of SIs [TCZ
10.68 vs. TNFI 3.03; IR ratio (95% confidence interval [CI]), 3.53 (1.52 to 8.18)], but not SAEs [21.36 vs. 14.72; 1.45 (0.94 to
2.25)], was significantly higher in the TCZ group compared with the TNFI group. However, after adjusting for covariates
using the Cox regression hazard analysis, treatment with TCZ was not associated with higher risk for SAEs [hazard ratio
(HR) 1.28, 95% CI 0.75 to 2.19] or SIs (HR 2.23, 95% CI 0.93 to 5.37).
Conclusions: The adjusted risks for SAEs and SIs were not significantly different between TCZ and TNFIs, indicating an
influence of clinical characteristics of the patients on the safety profile of the biologics in clinical practice.* Correspondence: mharigai.mpha@tmd.ac.jp
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Tocilizumab (TCZ), which is a humanized antibody
against the interleukin 6 (IL-6) receptor [1], inhibits sig-
naling mediated by IL-6 [2] and was first approved to
treat rheumatoid arthritis (RA) in Japan in 2008. The su-
perior efficacy of TCZ compared to a control drug or
placebo in RA patients has been demonstrated by a
series of clinical trials [3-12]. In clinical practice, TCZ
showed excellent effectiveness in patients with estab-
lished RA [13]. Safety profiles of TCZ in patients with
RA were clarified by the Japanese post-marketing sur-
veillance (PMS) program [14] and a meta-analysis [15].
In the PMS of TCZ, the most frequent category of ser-
ious adverse events (SAEs) was infection and the most
common infection was pneumonia. The incidence rate
(IR) of serious infections (SIs) per 100 patient-years (PY)
was 9.1, with older age, longer disease duration, respira-
tory diseases, and prednisolone dose ≥5 mg/day at base-
line identified as significant risk factors for development
of SIs during the first six months of treatment with TCZ
[14]. The favorable benefit-risk balance of TCZ has led to
the worldwide use of this biologic for treating RA [16].
In 2013, the European League Against Rheumatism
recommendations for the management of RA were up-
dated [17]. They now express no preference for the use
of a specific biological agent; this indicates that TCZ, as
well as tumor necrosis factor inhibitors (TNFIs) and
abatacept, can be first line biologics. Therefore, for the
clinical selection of biologics, it is necessary to compare
the efficacy and safety of TCZ with those of other bio-
logics. Systematic reviews [18,19] and meta-analyses [20]
indirectly comparing efficacy of TCZ with other bio-
logics showed that TCZ had similar response rates in pa-
tients with RA. Results from a clinical trial or study
comparing TCZ with another biologic have been reported.
Gabay et al. demonstrated that TCZ monotherapy was su-
perior to adalimumab monotherapy in RA patients who
are intolerant to methotrexate [21]. A Danish registry re-
ported the comparison of effectiveness between TCZ and
abatacept (ABA) [22] and found that declines in disease
activity during 48 weeks were similar between the drugs.
There are few data comparing the safety of TCZ with
other biologics. A meta-analysis found no significant dif-
ference in the risk of SIs between TCZ and other bio-
logics [23]. Using a Japanese single institution registry
with a relatively small number of patients, Yoshida et al.
reported the safety profiles of TCZ and TNFIs; IRs of
SAE were 15.9/100 PY in the TCZ group and 13.9/
100PY in the TNFI group [24]. However, to date, no de-
tailed comparison of SAEs between TCZ and TNFIs,
particularly the types and incidence of SIs, has been re-
ported. Additional direct observational studies are
needed to clarify the risk of use of TCZ versus TNFIs for
the development of SAEs and SIs in clinical practice.In this study, we utilized the database of the registry of
Japanese RA patients on biologics for long-term safety
(REAL), a prospective, multi-center cohort with a large
number of patients, and herein report IRs for each cat-
egory of SAEs for TCZ with hazard ratios (HRs) for




The REAL is a prospective cohort established to investi-
gate the long-term safety of biologics in RA patients.
Details of the REAL have been previously described [25].
In brief, 27 institutions participate in the REAL, includ-
ing 16 university hospitals and 11 referring hospitals.
The criteria for enrollment in the REAL include patients
meeting the 1987 American College of Rheumatology cri-
teria for RA [26], written informed consent, and starting
or switching treatment with biologics or starting, adding
or switching non-biologics at the time of enrollment in
the study. Enrollment in the REAL database was started in
June 2005 and closed in January 2012. Data were retrieved
from the REAL database on 5 March 2012 for this study.
This study was in compliance with the Helsinki Declar-
ation (revised in 2008). The REAL study was approved by
the ethics committees of the Tokyo Medical and Dental
University Hospital and all other participating institutions.
All ethical bodies that approved this study are shown in
the Acknowledgements section.
Data collection
Recorded baseline data for each patient includes demog-
raphy, disease activity, physical disability, comorbidities,
treatments, and laboratory data at the beginning of the ob-
servation period. A follow-up form was submitted every
six months to the REAL Data Center at the Department
of Pharmacovigilance of Tokyo Medical and Dental
University by site investigators to report the occurrence of
SAEs, current RA disease activity, treatments, and clinical
laboratory data [25]. Steinbrocker’s classification [27] was
used as the baseline measurement for the physical disabil-
ity of each patient instead of the Health Assessment Ques-
tionnaire Disability Index [28]. The investigators in each
hospital confirmed the accuracy of their data submitted to
the REAL Data Center. The center examined all data sent
by site investigators and made inquiries if needed to verify
accuracy of the data.
Patients
A flow chart of patients enrolled in this study from the
REAL is shown in Figure 1. By March 2012, 1,945 pa-
tients with RA were registered in the REAL. Of 1,236
patients who started infliximab (IFX), etanercept (ETN),
adalimumab (ADA) or TCZ at the time of enrollment or
Patients registered in the
REAL (n=1,945)
Patients who were treated with 
neither TNFI nor TCZ in the 
REAL (n=709)
Patients who started TNFI 
before 2008 (n=630)
Patients who started TNFI 
from 2008 or later (n=304)
Patients who started TCZ from 
2008 or later (n=302)
Patients who started TNFI or
TCZ in the REAL (n=1,236)
Figure 1 Flow chart of rheumatoid arthritis (RA) patients enrolled in this study from the REAL.
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who started TCZ (TCZ group). Patients who used both
TCZ and TNFIs at different periods were assigned to
the TCZ group. We then excluded 630 patients who had
started any of the TNFIs before 2008 because TCZ was
approved for RA in Japan in 2008, and identified 304 pa-
tients who started only TNFIs between 2008 and 2011
(TNFI group). The first TNFI of each patient in the
TNFI group was IFX for 117 patients, ETN for 80, and
ADA for 107. No patients started abatacept, golimumab,
or certolizumab pegol in the REAL during the time our
data were compiled for this study.
Follow-up
For patients in the TCZ group, the start date for the ob-
servation period was the date TCZ was first adminis-
tered. For patients in the TNFI group, the start of the
observation period was the date of the first administra-
tion of TNFI from 2008 to 2011. Observation was ended
at either 1.0 year after the start of the observation
period, or on the date of death of a patient, loss to follow
up, enrollment in clinical trials, when therapy with a bio-
logic of interest was discontinued for more than 90 days,
or on 5 March 2012, whichever came first. The period
following switching to another biologic was excluded
from this study. The date of the last administration of
each biologic was retrieved from medical records and re-
ported by the site investigators.
Definition of serious adverse events
Our definition of a SAE, including SIs, was based on the
report by the International Conference on Harmonization[29]. In addition, bacterial infections that required intraven-
ous administration of antibiotics and opportunistic infec-
tions were regarded as SAEs [30,31]. SAEs were classified
using the System Organ Class (SOC) of the medical dic-
tionary for regulatory activities (MedDRA version 16.0).
Statistical analysis
The chi-square test for categorical variables and Stu-
dent’s t-test or the Mann–Whitney test for continuous
variables were used for comparisons among groups. The
IR per 100 PY and incidence rate ratios (IRR) with their
95% confidence intervals (CIs) were calculated. Kaplan-
Meier methods and log-rank tests were used to compare
drug retention rates between the groups. The Cox re-
gression hazard model with the forced entry method
was used to calculate HRs of use of TCZ versus TNFIs
for SAEs and SIs. As a sensitivity analysis, we performed
the same analysis in patients treated with methotrexate
(MTX) at baseline, considering substantial differences in
clinical characteristics between MTX users and non-
users. These statistical analyses were conducted using
SPSS (version 20.0, SPSS Inc., Chicago, IL, USA). All P
values were two-tailed and P <0.05 was considered sta-
tistically significant.
Results
Demographic and clinical baseline characteristics
of patients
Baseline data for the patients are shown in Table 1.
Compared to the TNFI group, the TCZ group had lon-
ger disease duration (P <0.001), higher disease activity
(P = 0.019), more advanced disease stage (P <0.001), and
Table 1 Demographic and clinical characteristics of RA patients treated with TCZ or TNFIs




Age, years 59.20 ± 13.04 57.33 ± 15.18 0.275
Female, % 82.5 82.8 0.425
Disease duration, years 10.20 ± 8.64 7.96 ± 8.70 <0.001
Steinbrocker’s stagea 51.0 35.2 <0.001
(III or IV), %
Steinbrocker’s classa 29.1 19.4 0.005
(3 or 4), %
Previous biologic use, % 70.5 10.5 <0.001
Number of previous non-biological DMARDs ≥3, % 47.0 38.5 0.034
DAS28CRP (3)b 4.50 ± 1.23 (n = 233) 4.25 ± 1.24 (n = 279) 0.019
Pulmonary diseasesc, % 20.2 15.5 0.128
Diabetes mellitus, % 10.9 10.5 0.873
Liver diseasesd, % 6.6 4.6 0.281
Kidney diseasese, % 3.6 0.7 0.011
MTX use, % 53.0 85.5 <0.001
MTX dose, mg/week 8.41 ± 2.80 8.54 ± 2.28 0.237
Oral corticosteroids use, % 65.6 51.0 <0.001
PSL-equivalent dosef, mg/day 5.32 ± 3.19 4.99 ± 3.05 0.433
aSteinbrocker’s classification was used to define RA disease stages and classes; bDAS28CRP (3) was calculated based on three variables: swollen and tender 28-joint
counts and CRP; cpulmonary diseases included interstitial lung disease, chronic obstructive pulmonary disease, and asthma; dliver diseases included hepatitis B carrier,
hepatitis C carrier, fatty liver, hepatitis, primary biliary cirrhosis, positive anti-hepatitis C antibody, cholelithiasis, and abnormal liver function tests; ekidney diseases
included nephrotic syndrome, nephritis, renal failure, chronic kidney disease, renal hypertension, hemi-kidney, and elevation of serum creatinine; fthe oral corticosteroids
dose was converted to the equivalent prednisolone dosage. CRP; C-reactive protein; DAS28, disease activity score including 28-joint count; DMARDs, disease-modifying
antirheumatic drugs; MTX, methotrexate; PSL, prednisolone; RA, rheumatoid arthritis; TCZ, tocilizumab; TNFIs, tumor necrosis factor inhibitors.
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nificantly between the groups. A significantly higher rate
of the patients in the TCZ group had received three or
more non-biological disease-modifying anti-rheumatic
drugs before starting the biologic (P = 0.034), was biologic
non-naive (P <0.001), and was treated with oral corticoste-
roids (P <0.001). The proportion of patients treated with
MTX in the TCZ group was significantly (P < 0.001) lower
than in the TNFI group (n = 160 (53.0%) versus n = 260
(85.5%)). We also compared characteristics of MTX users
at baseline. Patients in the TCZ group had significantly
longer disease duration (P = 0.003), more advanced stage
(P = 0.005) and poorer physical function (P = 0.042) than
those in the TNFI group (Additional file 1: Table S1).
Retention rates for TCZ and TNFIs
The median (interquartile (IQR)) treatment period was
1.00 (0.50 to 1.00) year for the TCZ group and 1.00 (0.51
to 1.00) year for the TNFI group. The number of pa-
tients who discontinued biologics for any reason during
the observation period was 81 (26.8%) in the TCZ group
and 62 (20.4%) in the TNFI group, not a significant dif-
ference (P = 0.062 by chi-square). The development of
AEs was the most frequent reason for discontinuation inboth the TCZ group (n = 41, 50.6%) and the TNFI group
(n = 24, 38.7%). There was no significant difference in
the retention rates of the biologics for one year between
the two groups (71.0% in the TCZ group, 76.1% in the
TNFI group, P = 0.082 by Kaplan-Meier analysis and
log-rank test) (Figure 2).
Types and occurrence of SAEs
The IRs for SAEs are summarized in Table 2. Among the
606 patients, 82 SAEs were reported during the observa-
tion period; 48 in the TCZ group and 34 in the TNFI
group. The crude IRR, comparing the TCZ group with the
TNFI group for SAEs, was 1.45 (95% CI, 0.94 to 2.25) and
for SIs was 3.53 (95% CI, 1.52 to 8.18). There were no sig-
nificant differences in the IR of SAEs among the three
TNFIs (data not shown). For patients using MTX at base-
line, the IR of SAEs in the TCZ group was not significantly
higher than that in the TNFI group (IRR 1.48 95% CI, 0.85
to 2.61), whereas, the IR of SIs was significantly higher in
the TCZ group compared to the TNFI group (IRR 2.88
95% CI, 1.13 to 7.32). The IR of SIs in the TCZ group was
significantly higher than that in the TNFI group in pa-
tients with previous biologics exposure (4.4 (1.7 to 11.6)),
but not for SAEs (1.6 (0.8 to 3.0)).


























p=0.082 by log-rank test
Figure 2 Kaplan-Meier curves for time to discontinuation for
each group. Drug retention rates were compared using the
log-rank test between tocilizumab (TCZ) and tumor necrosis factor
inhibitors (TNFIs). The y axis shows the cumulative retention rates.
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at baseline; there were no significant differences in the
unadjusted IR of SAEs and SIs between MTX users and
non-users (data not shown). In the TCZ group, 70% of
the patients had previously used biologics; these patients
had safety profiles similar to the biologics-naïve patients
(data not shown).
In the TCZ group, there were 24 SIs including five
cases of opportunistic infections (herpes zoster (two);
Pneumocystis pneumonia (PCP) (one); pulmonary asper-
gillosis (one); and esophageal candidiasis (one)) and 19Table 2 Occurrence of SAEs in patients with RA treated with T
Types of SAEs
TCZ group, 224.68 P
IR (/100PY)
Total SAEs 21.36 (15.94 to 28.07)
Serious infection (SI) 10.68 (7.02 to 15.63)
Pulmonary infection 3.12 (1.39 to 6.12)
Non-pulmonary infection 7.57 (4.57 to 11.84)
Skin infection 1.78 (0.60 to 4.23)
Urinary tract infection 0.89 (0.18 to 2.85)
Gastrointestinal infection 0.89 (0.18 to 2.85)
Bone and joint infections 2.23 (0.84 to 4.88)
Sepsis 1.34 (0.37 to 3.56)
Other infection 0.45 (0.04 to 2.08)
Pulmonary disease, except infection 2.23 (0.84 to 4.88)
Cardiovascular or cerebrovascular disease 0.45 (0.04 to 2.08)
Malignancy 0.89 (0.18 to 2.85)
Death 1.78 (0.60 to 4.23)
Others 7.12 (4.24 to 11.29)
aCrude incidence rate per 100 PYs and crude incidence rate ratio with their 95% CI
interval; IR: incidence rate; IRR: incidence rate ratio; NA: not applicable; PY: patient-y
TNFIs: tumor necrosis factor inhibitors.non-opportunistic infections. In the TNFI group, of
seven cases with SIs, three were opportunistic infections
(herpes zoster (one); PCP (one); and pulmonary crypto-
coccosis (one)), and four non-opportunistic infections.
The respiratory system was the most frequent site of in-
fection in both groups (TCZ (seven) and TNFI (three)),
followed in the TCZ group by five in bone and joints
and four in skin and subcutaneous tissue. There were no
significant differences in the IR for pulmonary infection
(IRR 2.40 95% CI, 0.62 to 9.28), but the IR for non-
pulmonary infections was significantly higher in the
TCZ group compared to the TNFI group (IRR 4.37 95%
CI, 1.47 to 13.0). One perforation of the upper gastro-
intestinal tract developed in the TCZ group. No anaphyl-
actic reactions were reported in either group.
Evaluation of risk of TCZ for development of SAEs
compared to TNFI
We compared patients who had and had not experi-
enced SAEs using a univariate analysis and selected vari-
ables for the multivariate Cox regression hazard analysis
to evaluate the risk of the use of TCZ for the develop-
ment of a SAE. After adjusting for age, gender, disease
activity score including 28-joint count C-reactive protein
(3), comorbidity, use of oral corticosteroids (prednisolone-
equivalent dose) ≥5 mg/day, and Steinbrocker’s class, the
hazard ratio (HR) of the use of TCZ compared to the use
of TNFI for developing SAEs was 1.28 (95% CI, 0.75 to
2.19, P = 0.370), not significantly elevated (Table 3). Sig-
nificant risk factors influencing the development of SAEsCZ or TNFIsa
Y TNFI group, 231.01 PY TCZ versus TNFI
IR (/100PY) Crude IRR (95% CI)
14.72 (10.37 to 20.32) 1.45 (0.94 to 2.25)
3.03 (1.35 to 5.95) 3.53 (1.52 to 8.18)
1.30 (0.36 to 3.46) 2.40 (0.62 to 9.28)
1.73 (0.58 to 4.12) 4.37 (1.47 to 12.99)
0.43 (0.04 to 2.02) 4.11 (0.46 to 36.80)
0.43 (0.04 to 2.02) 2.06 (0.19 to 22.68)
0.43 (0.04 to 2.02) 2.06 (0.19 to 22.68)
0 NA
0 NA
0.43 (0.04 to 2.02) 1.03 (0.06 to 16.44)
2.16 (0.82 to 4.74) 1.03 (0.30 to 3.55)
2.16 (0.82 to 4.74) 0.21 (0.02 to 1.76)
1.30 (0.36 to 3.46) 0.69 (0.11 to 4.10)
0.87 (0.17 to 2.78) 2.06 (0.38 to 11.23)
6.06 (3.47 to 9.90) 1.18 (0.57 to 2.41)
were calculated for each category of serious adverse events. CI: confidence
ear; RA: rheumatoid arthritis; SAEs: serious adverse events; TCZ: tocilizumab;
Table 3 Factors influencing development of SAEs in patients with RA treated with TCZ or TNFIsa
Variable All patients MTX users
HR (95% CI)c P valuec HR (95% CI)d P valued
Age by decade 1.47 (1.15 to 1.88) 0.002 1.58 (1.07 to 2.35) 0.022
Female 0.74 (0.40 to 1.38) 0.345 0.96 (0.38 to 2.47) 0.940
DAS28CRP (3) 1.06 (0.98 to 1.14) 0.151 1.06 (0.76 to 1.48) 0.744
Comorbidityb 1.86 (1.07 to 3.24) 0.029 2.10 (0.92 to 4.79) 0.077
PSL ≥5 (mg/day) 1.72 (1.01 to 2.93) 0.047 1.64 (0.74 to 3.63) 0.223
Steinbrocker’s Class 3 or 4 1.37 (0.77 to 2.43) 0.287 1.10 (0.47 to 2.60) 0.825
Tocilizumab 1.28 (0.75 to 2.19) 0.370 1.21 (0.55 to 2.65) 0.632
aCox regression analysis with the independent variables included in the Table; bcomorbidity included pulmonary diseases, diabetes mellitus, liver diseases, and
kidney diseases; cCox regression analysis was applied in all patients; dCox regression analysis was applied in patients who were treated with MTX at baseline. CI:
confidence interval; CRP: C-reactive protein; DAS28CRP (3): 3-variable disease activity score including 28-joint count; HR: hazard ratio; MTX: methotrexate; PSL:
prednisolone RA: rheumatoid arthritis; SAEs: serious adverse events; TCZ: tocilizumab; TNFIs: tumor necrosis factor inhibitors.
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0.002), the presence of a comorbidity (HR 1.86, 95% CI,
1.07 to 3.24, P = 0.029), and the use of oral corticosteroids
(prednisolone-equivalent dose) ≥5 mg/day (HR 1.72, 95%
CI, 1.01 to 2.93, P = 0.047) (Table 3). We evaluated the risk
of use of TCZ for development of SAEs in patients given
MTX at baseline as a sensitivity analysis, and found the
HR of use of TCZ was 1.21 (0.55 to 2.65, P = 0.632) com-
pared to the use of TNFI (Table 3).Evaluation of risk of TCZ for development of SIs
compared to TNFIs
We next investigated the risk of use of TCZ compared to
the use of TNFI for development of SIs. After comparing
patients who had and had not experienced SIs using a uni-
variate analysis, we selected adjusting factors for the multi-
variate analysis. The HRs for using TCZ compared with
TNFI were 2.23 (95% CI, 0.93 to 5.37; P = 0.074) in all the
patients and 1.93 (95% CI, 0.72 to 5.17; P = 0.190) in pa-
tients treated with MTX at baseline (Table 4). The use of
oral corticosteroids (prednisolone-equivalent dose) ≥5 mg/
day was a significant risk factor influencing the develop-
ment of SIs (HR 2.26, 95% CI, 1.02 to 5.01, P = 0.046).Table 4 Factors influencing development of SI in patients wit
Variable All patients
HR (95% CI)c P
Age by decade 1.34 (0.95 to 1.89)
Female 3.27 (0.77 to 13.98)
Comorbidityb 2.20 (0.95 to 5.11)
PSL ≥5 (mg/day) 2.26 (1.02 to 5.01)
Tocilizumab 2.23 (0.93 to 5.37)
aCox regression hazard models were performed using the independent variables in
mellitus, liver diseases, and kidney diseases; cCox regression analysis was applied in
with MTX at baseline. CI: confidence interval; HR: hazard ratio; MTX: methotrexate; P
tocilizumab; TNFIs: tumor necrosis factor inhibitors.Discussion
In this study, we conducted a direct comparison of the
safety of TCZ with TNFIs in clinical practice, using a
prospective, multi-center cohort with the largest possible
number of patients. We demonstrated that the un-
adjusted IR of SAEs was not significantly higher in the
TCZ group compared with the TNFI group, whereas the
unadjusted IR of SIs of the TCZ group was 3.5-fold
higher than the TNFI group. However, after adjusting
for covariates, the use of TCZ compared to the use of
TNFIs was not significantly associated with the develop-
ment of SAEs or SIs.
Some studies have investigated the safety of TCZ in
RA patients [4,13,15,32-35]. It has been reported that
the IR of SAEs was 20 to 30/100PY and that the most
frequent SAE was infection (5 to 9/100PY) [4,14,15,36].
In the present study, the IRs of SAEs (21.36/100PY) and
SIs (10.68/100PY) were similar to those of previous re-
ports. The most frequently reported category of SAE in
our study was infection and the incidence rate of non-
pulmonary infection in the TCZ group was conspicu-
ously higher compared to the TNFI group (7.57/100PY
versus 1.73/100PY). Among non-pulmonary infections,
skin and bone and joints were common sites in the TCZh RA treated with TCZ or TNFIsa
MTX users
valuec HR (95% CI)d P valued
0.093 1.31 (0.86 to 2.00) 0.210
0.110 2.20 (0.49 to 9.93) 0.305
0.067 2.49 (0.87 to 7.10) 0.088
0.046 2.04 (0.77 to 5.44) 0.154
0.074 1.93 (0.72 to 5.17) 0.190
cluded in the Table; bcomorbidity included pulmonary diseases, diabetes
all patients; dCox regression analysis was applied in patients who were treated
SL: prednisolone; RA: rheumatoid arthritis; SI: serious infection; TCZ:
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tions, as well as pulmonary infections, were frequently
observed in patients treated with TCZ [4,15,24,33,37,38].
Although the reasons for the high incidence rates of
these types of infections in patients given TCZ have not
been explained, special attention should be paid, not
only to pulmonary infections, but also to skin infections
in TCZ users.
We found no increased risk for the use of TCZ com-
pared to the use of TNFIs for the development of SIs after
adjusting for covariates at baseline. It is notable that the
unadjusted IR of SIs in the TCZ group (10.7 (7.02 to 15.6))
was significantly increased compared to the TNFI group
(3.53 95%CI, 1.52 to 8.18); this can be explained by several
factors. The multivariate analysis indicated that the differ-
ences in clinical characteristics of the patients between the
two groups influenced the difference in IRs of SIs (Table 4).
The use of oral corticosteroids (prednisolone-equivalent
dose) ≥5 mg/day was a significant risk factor for SIs in our
study. Previous studies have reported that use of oral cor-
ticosteroids significantly increased the risk of SIs in pa-
tients undergoing treatment with biologics [29,39,40].
Patients in the TCZ group of our study used concomitant
corticosteroids more frequently. It has been shown that
the presence of comorbidities increased the risk of SIs in
RA patients [41]. Although the HR of comorbidities was
2.20 in our study, it did not achieve statistical significance
(P = 0.067). Relatively more patients in the TCZ group
than in the TNFI group had at least one comorbidity
(34.1% for the TCZ group, 27.3% for the TNFI group, P =
0.069). These data indicate that patients in the TCZ group
may be more predisposed to infections than those in the
TNFI group.
The low IR of SIs in the TNFI group apparently con-
tributed to the increased IRR of SIs. The IR of SIs in the
TNFI group in our study (3.03/100 PY) was lower than
in previous studies (5 to 6/100PY) [25,29,42,43], result-
ing in an increased IRR when comparing TCZ and
TNFIs. We previously reported a significant decrease
over time of the risk for SIs with TNFI treatment, pos-
sibly explained by evidence-based risk management of
RA patients given TNFIs [44]. In the present study, pa-
tients in the TNFI group started TNFIs in or after 2008,
five years after the approval of IFX for RA in Japan. In-
formation about risk of SIs in patients given TNFIs from
observational studies has been extensively shared among
Japanese rheumatologists, leading to improved risk man-
agement and, in consequence, lowered IRs for SIs in the
TNFI group [44]. To accurately compare the outcome
between a new drug and an existing one, differences in
the calendar year of drug approval should be considered.
Therefore, in our study, we compared the use of two bi-
ologics, TCZ and TNFIs, in clinical practice during the
same time period.There are potential limitations of this study. First, we
have to mention the possibility of selection bias. The pa-
tients in this study were enrolled from university hospi-
tals or referral hospitals that are dedicated to the
treatments of RA, which may indicate unidentified selec-
tion bias. However, because almost all patients who were
registered from the participating hospitals to the all-
cases post-marketing surveillance programs for each bio-
logical DMARD were enrolled in the REAL, selection
bias was substantially low. Second, although there is
concern about information bias, such as recall bias and
reporting bias, in epidemiological studies in general, we
collected patient data using the same case report form
prospectively, which should overcome the misclassifica-
tion and underestimation of SAEs derived from these
types of bias. Third, clinical practice is always accom-
panied by the indication bias occurring when a drug is
preferentially prescribed to patients with different base-
line characteristics. In this study, it was notable that the
difference in the percentage of patients who were given
MTX at baseline between the two groups was signifi-
cant, which would have affected the results of our study.
To address this possibility, we estimated the risk of SAEs
and SIs in patients with concomitant MTX in addition
to the whole study population, and found them to be
similar. Fourth, we did not investigate the comparison of
effectiveness between the two groups due to incomplete
data about disease activity in some patients.
Conclusions
The adjusted risks for SAEs and SIs between TCZ and
TNFI were not significantly different in clinical practice,
although significantly higher IRs for SIs were observed
in the TCZ group, possibly attributable to more infection
susceptible clinical characteristics of the patients in the
TCZ group.
Additional file
Additional file 1: Demographic and clinical characteristics of RA
patients treated with methotrexate at baseline. This file provides
demographic and clinical characteristics of RA patients given
methotrexate at baseline in this study.
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